Formycon (FYB)

Business description

Formycon is a biotechnology company focused on biosimilars. The lead product is FYB201, a Lucentis biosimilar in Phase III. FYB203 is an Eylea biosimilar in the preclinical stage. They are both partnered. It also has two unpartnered biosimilars: FYB202, a biosimilar candidate of Stelara; and FYB205, an undisclosed biosimilar.

Biosimilar opportunities

QuickView | Pharmaceutical & healthcare | 07/11/2013

Formycon is preparing to exploit the emerging opportunity for biosimilars. By 2020, protein-based therapeutics with sales of >$70bn will lose patent protection. Its first two biosimilar programmes are progressing well and could be partnered in 2015. There should be significant demand for Formycon products because of the size of the markets and the challenges of developing biosimilar products with the correct characteristics.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€335.4m
Last close€35.900
High / Low (52 weeks)€39.2 / €26.3
Stock market listingDB
Forecast net debt (m)N/A
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual12.410.537.1
Relative *6.219.131.4

* % Relative to local index

Company news